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Carbohydrate metabolism during fasting in chronic hemodialysis pa-
tients. Carbohydrate metabolism was studied during a 72-hr fast in Ii
nondiabetic endstage renal disease (ESRD) patients on chronic hemodi-
alysis and six normal subjects. Blood was obtained every 12 hr for
metabolic substrate, insulin, and potassium concentrations. Serum
potassium concentrations were significantly higher in the ESRD pa-
tients at the end of each fasting day, and two patients were removed
before completion of the fast when severe hyperkaleniia developed.
Mean blood glucose, alanine, pyruvate, 3-hydroxybutyrate, and serum
insulin concentrations were similar in the two groups. Mean blood
lactate concentration tended to be higher in the ESRD group. Mean
blood acetoacetate and plasma free fatty acid (FFA) concentrations
were lower in the ESRD group. When compared to serum insulin levels,
the FFA concentration was lower in the ESRD group.
Métabolisme glucidique pendant le jeune chez des malades en hémodia-
lyse chronique. Le métabolisme glucidique a été étudié pendant unjeüne
de 72 hr chez 11 hemodialysés chroniques non diabétiques (ESRD) et
chez 6 sujets normaux. Du sang était prélevé toutes les 12 hr pour des
mesures de substrat metabolique et des les concentrations d'insuline et
de potassium. Les concentrations de potassium sériques étaient signifi-
cativement plus hautes chez les malades en ESRD a Ia fin de choque
jour de jeUne, et deux malades ont été retires avant Ia fin du jefine car
une hyperkaliémie sévère est apparue. Les concentrations moyennes
sanguines de glucose, alanine, pyruvate, /3-hydroxybutyrate, et l'insu-
line sérique étaient identiques dans les deux groupes. La concentration
moyenne de lactate sanguin tendait a être plus élevée dans le groupe en
ESRD. Les concentrations moyennes sanguines d'acétoacétate et d'a-
cide gras libres plasmatiques (FFA) étaient plus faibles dans Ic groupe
ESRD. Lorsqu'elle btait comparée au niveau d'insuline sérique, Ia
concentration de FFA était plus faible dans le groupe ESRD.
Disturbances of carbohydrate metabolism frequently occur in
nondiabetic patients with chronic renal failure [1]. Glucose
intolerance most often is described but occasionally patients
exhibit spontaneous fasting hypoglycemia [2—8]. Substrate limi-
tation [3, 5, 81, impaired hepatic gluconeogenesis [5], and
prolongation of insulin half-life [91 each may result in fasting
hypoglycemia in such patients, although other mechanisms
have been proposed [4, 6, 7]. The present study was designed to
examine glucose metabolism in chronic hemodialysis patients
during a 72-hr fast.
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Methods
Eleven nondiabetic endstage renal disease (ESRD) patients
on chronic hemodialysis and six normal subjects were evaluat-
ed after written informed consent was obtained. The two groups
were matched for weight, triceps skin-fold thickness, midarm
muscle circumference, and serum albumin level. The ESRD
patients were divided further into two groups: one with liver
disease manifested by elevated hepatic enzyme levels and/or
abnormal liver biopsy specimens, and one with normal liver
function. All patients were admitted to the General Clinical
Research Center at the University of Alabama in Birmingham, 6
to 12 hr after hemodialysis. Three of the 11 patients had been
taking /3-blocking drugs prior to the fast. One was on metopro-
lol, 50 mg twice a day, and two patients were on propranolol, 40
mg/24 hr. All medications, except digoxin, were discontinued
36 hr prior to fasting. Patients were fed at 6 P.M. and began a 72-
hr fast at 9 P.M. As no attempt was made to withdraw all food
until the onset of the fast, that is, at 9 P.M. the initial (0 hr)
studies are not representative of the basal, postabsorptive state.
ESRD patients were allowed 10 ml of water/kg body weight/24
hr, while the normal subjects had free access to water. Blood
was obtained every 12 hr for glucose, insulin, potassium,
lactate, pyruvate, /3-hydroxybutyrate, acetoacetate, alanine,
glycerol, and free fatty acid levels. The fast was terminated at
72 hr, and the ESRD patients underwent hemodialysis the next
morning. The protocol was similar for the normal subjects
except that they did not undergo dialysis. All individuals were
ambulatory during the period of fasting.
Glucose and potassium levels, respectively, were determined
by the glucose hexokinase and ion-selective electrode methods.
Serum insulin levels were measured by radioimmunoassay [10].
Blood lactate, pyruvate, /3-hydroxybutyrate, acetoacetate, ala-
nine, and glycerol levels were determined enzymatically from
perchloric acid extracts of whole blood [11, 12]; plasma free
fatty acid levels were determined by the copper colorimetric
method [12]. The statistical significance of differences between
group means was determined by Student's t test for unpaired
samples. The carbon dioxide content data in the two groups
were compared by analysis of the individually fitted quadratic
coefficients by Student's t test [13].
Results
The clinical and laboratory features of the three groups are
shown in Table 1. The ESRD group was significantly older than
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Table 1. Clinical and laboratory features of the patient population
ESRD
Normal
subjects(N=6) Normal liver(N=5) Liver disease(N=6)
Sex
Male 2 1 2
Female 4 4 4
Age, yearsa 29 3 44 6' 45 5b
Weight, kg 74 6 69 5 69 7
TSF, % of standard 124 26 168 30 107 22
MAMC, % of standard 98 4 99 6 96 4
Albumin, g/dl 4.0 0.3 4.2 0.3 4.2 0.1
SGOT, IU/di 21 I 12 2b 123 88
SGPT,IU/dl 14 11 6 lb 136 117
GGT,IUIdl 10 2 8 2 114 32bc
Prothrombin time, sec 11.7 0.2 12.0 0.3 12.7 0.2b
Abbreviations: TSF denotes triceps skin-fold thickness; MAMC,
midarm muscle circumference.
Mean SE.
b P < 0.05, compared to normal subjects.
P < 0.05, compared to ESRD patients with normal liver function.
the normal subjects but was similar with respect to body
weight, anthropometric measurements, and serum albumin
concentration. The ESRD patients with normal liver function
had significantly lower serum glutamic oxalacetic transaminase
(SGOT) and SGPT levels than did normal subjects. In the
ESRD group with liver disease, the GGT level was elevated, as
compared to patients without liver disease, and the prothrom-
bin time was prolonged when compared to normal subjects. The
mean blood glucose concentration in patients with normal liver
function equalled 121 mg/dl at the beginning of the fast, and 86,
70, and 64 mg/dl, respectively, at the end of 24, 48, and 72 hr of
fasting. In patients with abnormal liver function, the blood
glucose level equalled 110 mg/dl at the onset of the fast, and 79,
77, and 69 mg/dl, respectively, after 24, 48, and 72 hr. In this
and all other respects, the ESRD group with normal liver
function was similar to the ESRD group with liver disease.
Therefore, the data for the ESRD groups are combined. The
mean (± SE) BUN equalled 13 1 in normal subjects and 50 5
in ESRD patients at the onset of fasting.
Three ESRD patients were unable to complete the full 72-hr
fast. One patient with normal liver function became lighthead-
ed, with diaphoresis, tachycardia, and a blood glucose level of
42 mgldl, after 60 hr of fasting. At the same time, her blood
alanine measured 61 jmoles/liter. Her symptoms and signs
resolved after she was given 50 ml of 50% dextrose in water
intravenously and fed. Two additional patients were removed
from the study when serum potassium levels reached 7.1 and
7.2 mEq/liter. These patients were given dextrose in water,
insulin, and bicarbonate intravenously, sodium polystyrene
sulfonate by mouth and by rectal enema, and were hemodia-
lyzed within 4 hr. Neither patient had received a 13-blocker prior
to fasting.
It is noteworthy that eight of 11 ESRD patients had serum
potassium levels 5.3 mEq/liter at some time during the fast,
while none of the normal subjects reached that level. Since
serum potassim concentration tended to rise during the fast in
the ESRD patients, it was necessary to administer sodium
bicarbonate intravenously (average of 37 mEq/patient/24 hr)
and sodium polystyrene sulfonate rectally (average of 36 g/pa-
tient/24 hr). Nonetheless, serum potassium levels were signifi-
cantly higher in the ESRD group than in the normal subjects at
the end of each day of fasting (P < 0.05, Table 2). Interestingly,
hyperkalemia consistently resolved after resumption of food
intake, 4 to 12 hr prior to hemodialysis. To exclude any
persistent effect of /3-blocking agents, the potassium data were
analyzed after excluding the three patients who had received
such drugs prior to fasting (Table 3). It can be seen that the
mean serum potassium concentration was still significantly
higher in ESRD patients than in normal subjects after 24, 48,
and 72 hr of fasting (P <0.05). Levels of carbon dioxide content
(Table 2) were alike in both groups.
Glucose, insulin, and metabolic substrate levels are shown in
Table 4. The mean blood glucose concentrations were similar
throughout the fast, equalling 66 mg/dl in the ESRD group and
60 mg/dl in normal subjects after 72 hr. Serum insulin levels
were alike in the two groups and appropriately suppressed
throughout the fast. Likewise, the insulin/glucose ratios were
the same in the two groups, equalling 0.2 or less in both groups
at each interval of fasting after 0 hr.
Blood lactate levels were higher in the ESRD group (P <
0.05) except at the beginning and the end of the fast. Neither
pyruvate levels nor lactate/pyruvate ratios were different in the
two groups. Blood alanine concentrations initially were higher
in ESRD patients, although only the 12-hr value achieved
statistical significance (P < 0.05). Subsequently, alanine levels
were alike in both groups.
Plasma free fatty acid (FFA) levels increased from 696 to
1659 tEq/liter in normal subjects during the fast. In compari-
son, FFA concentrations were significantly lower in the ESRD
patients, equalling 336 Eq/liter at the onset, and only 907
SEq/liter after 72 hr of fasting, despite serum insulin levels
which were no different than those of normal subjects. When
grouped according to serum insulin levels, the mean plasma
FFA concentrations in the ESRD group were significantly
lower than in normal subjects (Table 5). The free fatty acid
levels in those patients who were not receiving 13-blockers prior
to fasting are shown in Table 3. Once again, the mean FFA
concentrations in the ESRD group were significantly lower than
in normals at each interval of fasting except for 0 and 48 hr. The
blood glycerol concentration (Table 4) was significantly lower
in ESRD patients at 12 hr (P = 0.004) and 24 hr (P = 0.04), but
only marginally lower at 36 hr (P = 0.07). The glycerol levels
were the same in the two groups at 72 hr.
Blood acetoacetate levels (Table 4) consistently were higher
in normal subjects than in ESRD patients. These differences
were statistically significant (P < 0.05) between 12 and 48 hr of
fasting. In contrast, mean /3-hydroxybutyrate values were simi-
lar in the two groups throughout the fast. The /3-hydroxybuty-
rate/acetoacetate ratio was significantly higher in the ESRD
group than in the normal subjects (P < 0.00 1).
Discussion
Few available data describe the response of ESRD patients
on chronic hemodialysis to prolonged fasting [3, 51. Our obser-
vations suggest that, in well dialyzed subjects, extended fasting
generally is accompanied by suppression of endogenous insulin
secretion and the maintenance of normal blood glucose levels.
Previously, we suggested that impairment of hepatic gluconeo-
224 Du,nhauld el a!
Table 2. Serum potassium and carbon dioxide content during 72-hr fasta
Fasting hour
genesis may cause hypoglycemia in fasting patients with ESRD
[5]. It is clear from the present study that mild hepatic dysfunc-
tion alone is not likely to cause hypoglycemia during prolonged
fasting. However, a symptomatic fall in the blood glucose
concentration occurred in one ESRD patient with normal
hepatic function. This was associated with a blood alanine level
of 61 !moles/liter, which was the lowest alanine value observed
in either group. This is consistent with previous observations
[3, 5] that fasting hypoglycemia in ESRD patients may result
from substrate limitation.
The majority of our ESRD patients required treatment for
hyperkalemia as fasting progressed and serum insulin levels
fell. Since potassium intake was zero in both groups, the
observed rise in serum potassium concentrations in ESRD
patients most likely resulted from the inability to excrete an
influx of potassium from the intracellular compartment. Similar
levels of carbon dioxide content and, by inference, hydrogen
ion concentration in the two groups indicate that internal pH
mediated potassium shifts were not the cause of hyperkalemia
in the ESRD group. Two of our patients had received proprano-
lol, 40 mg124 hr, and one received metoprolol, 100 mg/24 hr, up
until 36 hr prior to fasting. Although the half-life of propranolol
is 6.2 hr or less in patients with ESRD [14], that of metoprololis
unknown. Thus, we cannot exclude some lingering effect of
these agents on internal potassium distribution. However, since
the mean serum potassium concentration in those ESRD pa-
tients who had not received /3-blockers was significantly higher
at 24, 48, and 72 hr of fasting, than that of normal controls, we
suggest that persistent /3-blockade was of minimal, if any,
importance. These observations, as well as the resolution of
hyperkalemia after the patients ate, suggest that insulin may
play a significant role in the control of internal potassium
balance in fasting ESRD patients. However, since serum insulin
and potassium values did not correlate statistically, it is possi-
ble that other factors such as catecholamines are of importance
[15]. Irrespective of the mechanism, our data demonstrate that
hemodialysis patients are at considerable risk of developing
severe hyperkalemia during fasting.
A diminished plasma FFA concentration previously has been
described in nondialyzed patients with chronic renal insufficien-
cy after a 12-hr fast [16]. However, several of these patients
were treated with /3-blocking agents which, because of their
antilipolytic effect [17], may have contributed to the low FFA
levels. In our study, when the three patients who had received
/3-blockers were excluded, the FFA levels in ESRD patients
were still significantly lower than those of normal subjects at
each interval of fasting except for 0 and 48 hr. The reason for
the observed low levels of FFA in our patients is unclear. Our
data do not permit us to distinguish between increased FFA
utilization and decreased lipolysis. Neither can we be certain
whether the low FFA levels relate to a change in insulin
sensitivity or some other factor, such as catecholamines. How-
ever, these observations are consistent with earlier demonstra-
tions that FFA levels fall to a greater extent, in response to
0 12
Potassium, mEqilirer
NormaP'
ESRD
P
CO2 content, mEqiliter
Normal
ESRD
24 36 48 60 72
3.9 0.1 3.9 0.2 4.1 0.1 4.3 0.2 4.3 0.1 4.5 0.2 4.3 0.1
4.4 0.2 4.5 0.2 5.2 0.3 4.9 0.2 5.4 0.3 4.8 0.5 5.0 0.2
(9) (8) (8) (9) (7)
0.06 NS 0.02 0.05 0.0! NS 0.01
23.8 1.2 23.5 1.3 20.0 1.4 18.7 1.7
23.2 1.2 22.8 0.8 22.4 1.2 19.9 1.6
(9) (9)
a The number in parentheses indicates the number of patients other than II; the number of normal subjects is six.
b Mean SE.
Table 3. Serum potassium and free fatty acid levels during 72-hr fasta
0 12 24
Fasting hour
36 48 60
P
72
Potassium, mEqiliter
Normal' 3.9 0.1 3.9 0.2 4.1 0.1 4.3 + 0.2 4.3 0.1 4.5 0.2 4.3 0.1
ESRDC 4.5 0.3 4.7 0.2 5.3 0.4 5.0 0.2 5.4 0.4 4.8 0.2 4.9 0.2
(7) (6) (6) (6) (5)p < 0.1 > 0.05 < 0.1 > 0.05 <0.02 < 0.1 > 0.05 <0.02 < 0.4 > 0.3 < 0.05
Free fatty acids, EqIliter
Norma! 696 142 1032 73 1264 184 1187 90 1272 151 1278 114 1659 271
ESRD 373 88 624 138 678 168 567 94 798 182 827 14! 858 161
(7) (7) (7) (6) (5) (5) (5)
<0.1 > 0.05 <0.05 < 0.05 <0.001 <0.1 > 0.05 < 0.05 < 0.05
a Number in parentheses indicates the number of patients other than eight; the number of normal subjects is six.
Mean SE.
ESRD patients, excluding those exposed to /3-blockers.
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Table 4. Metabolic substrate and serum insulin levels during 72-hr fasta
Fasting hour
0" 12 24 36 48 60 72
Glucose, mgldl
Normalc 95 7 89 3 79 5 76 4 62 2 64 3 60 3
ESRD 115 5d 90 2 82 3 79 5 74
(10)
4 71 5
(9)
66 2
(8)
Insulin, UIml
Normal 46± 16 9± 1 10± 1 9± 1 9± 2 7± 1 8± 1
ESRD 49± 8 17± 4 13±3 12± 2 9±
(10)
2 9±2
(9)
7± 1
(8)
Lactate, molesIliter
Normal 578 81 405 34 413 35 426 22 432 37 449 35 527 27
ESRD 654 86 680 55" 553 28d 711 54" 574
(10)
83 659 76d
(9)
604 53
(8)
Pyruvate, jmolesIliter
Normal 83 20 54 9 63 16 42 5 66 20 97 26 91 21
ESRD 68 11 54 7 49 4 67 4" 56
(10)
7 90 18
(9)
93 31
(8)
Alanine, moles/liter
Normal 212 14 148 8 146 9 136 9 142 17 132 11 134 12
ESRD 332 57 294 45" 208 21 198
(10)
3 177
(9)
22 163 27
(9)
154 33
(8)
Free fatty acids, pEq/liter
Normal 696 142 1032 73 1264 184 1187 90 1272 151 1278 114 1659 271
ESRD 336
(9)
77" 584
(9)
111" 648 133"
(9)
709
(9)
121" 824
(7)
129" 860 171
(7)
907 124d
(7)
f3-Hydroxybutyrate, mo1es/Iiter
Normal 128 19 239 65 346 115 543 144 827 196 1013 388 1288 276
ESRD 122 17 163
(9)
22 230 36 334
(9)
58 578
(10)
99 774 162
(8)
1381 247
(8)
Acetoacetate, molesIliter
Normal 45 19 82 9 123 43 206 35 253 42 346 89 452 53
ESRD 32 6 37
(10)
5" 50 9d 52
(10)
10" 88
(10)
19" 150 60
(8)
264 83
(8)
Glycerol, moles/liter
Normal 62 8 529 78 177 59 249 79 — — 186 33
ESRD 46 9 306 23" 69 18" 121
(10)
21 — — 174 37
(8)
The number in parentheses indicates the number of patients other than 11; the number of normal subjects is six.
b Values at 0 hr are postprandial.
Mean SE.
"P < 0.05.
Table 5. Relationship of insulin level to free fatty acid concentration
Serum insutin, U/ml
0 to 10 11 to 20 21 to 30 >30
Free fatty acids,
EqI1iter
Normala
ESRD
P
1235 72
886 69
<0.002
1293 163
656 80
<0.001
507
—
135
—
763 294
317 79
<0.07
Mean SE.
insulin or glucose infusions, in patients with chronic renal
failure than in normal subjects [18, 191.
Mean levels of blood lactate tended to be higher in our ESRD
patients, but the lactate/pyruvate ratios were not elevated in
either of the two groups. On the other hand, the ratio of /3-
hydroxybutyrate/acetoacetate was significantly higher in the
ESRD patients, largely as the result of depressed levels of
acetoacetate. Whether this resulted from increased peripheral
utilization or decreased hepatic production of ketoacids cannot
be ascertained from our data.
We conclude that, in response to prolonged fasting, hemodi-
alysis patients demonstrate (1) an increased risk of developing
life-threatening hyperkalemia, (2) normal glucose and insulin
responses, (3) normal blood alanine concentrations and elevat-
ed levels of lactate, (4) decreased concentrations of plasma
FFA and blood glycerol, and (5) depressed blood levels of
acetoacetate. Hypoglycemia may result in those patients with
limited availability of gluconeogenic substrate. The combina-
tion of ESRD and minimal liver dysfunction is insufficient to
produce hypoglycemia during prolonged fasting.
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